This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.
Protocol Amendment History
7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-10-10; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting2023-11-06